Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/221691
Title: Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
Author: Zugasti, Inés
López Guerra, Mònica
Castaño Díez, Sandra
Esteban, Daniel
Avendaño Pita, Alejandro
Pomares, Helena
Pérez, Ana
García Ávila, Sara
Padilla Conejo, Irene
Fuente Montes, Cristina de la
Martínez Roca, Alexandra
Merchán Muñoz, Beatriz
Jiménez Vicente, Carlos
Guijarro Tomas, Francisca
Ramón Álamo, José
Cortés Bullich, Albert
Torrecillas, Victor
Mont de Torres, Lucía
Carcelero, Esther
Riu Viladoms, Gisela
Zamora, Lurdes
Bargay, Joan
Triguero, Ana
Suarez Lledó, María
Queralt Salas, Maria
López Cadenas, Felix
Ramos, Fernando
Xicoy Cirici, Blanca
Valcárcel, David
Arnan, Montserrat
Martínez, Carmen
Rovira, Montserrat
Fernández Avilés, Francesc
Díez Campelo, María
Esteve Reyner, Jordi
Díaz Beyá, Marina
Keywords: Leucèmia mieloide
Terapèutica
Myeloid leukemia
Therapeutics
Issue Date: 26-Apr-2025
Publisher: Springer Science and Business Media LLC
Abstract: BackgroundHigh-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell transplantation (allo-SCT). The most frequent pre-allo-SCT treatment is monotherapy with hypomethylating agents (HMA), but approximately 40% of patients cannot proceed to allo-SCT, mainly due to disease progression. Recent evidence suggests that combining HMA with venetoclax (HMA/VEN) could increase HMA efficacy in HR-MDS but it remains unclear if this combination could bridge more patients to allo-SCT.MethodsWe retrospectively evaluated HMA/VEN as a bridge to allo-SCT in 30 patients with HR-MDS or CMML eligible for transplant. Eighteen patients were treatment-na & iuml;ve and 12 were refractory or relapsed (R/R).ResultsAs defined by the IWG 2023 criteria, the overall response rate (ORR) was 90% and the composite complete response rate was 77%. For the R/R patients, ORR was 83%. The allo-SCT rate was 83%, and the allo-SCT rate of those patients treated exclusively with HMA/VEN without further bridge therapies was 76%. One- and two-year post-allo-SCT survival was 75% and two-year cumulative incidence of relapse was 30.5%. Follow-up of measurable residual disease identified some molecular relapses that were controlled with preemptive treatment.ConclusionsOur findings indicate that HMA/VEN combination therapy shows promise as a bridging strategy to allo-SCT in HR-MDS and CMML.
Note: Reproducció del document publicat a: https://doi.org/10.1186/s40164-025-00652-5
It is part of: Experimental Hematology and Oncology, 2025, vol. 14
URI: https://hdl.handle.net/2445/221691
Related resource: https://doi.org/10.1186/s40164-025-00652-5
ISSN: 2162-3619
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
s40164-025-00652-5.pdf2.19 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons